Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.

@article{Johnson2012GlatiramerAF,
  title={Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.},
  author={Kenneth P. Johnson},
  journal={Expert review of neurotherapeutics},
  year={2012},
  volume={12 4},
  pages={371-84}
}
Glatiramer acetate (GA; Copaxone(®), Teva Pharmaceuticals Inc.), approved in the USA in 1996 and EU in 2001 as first-line treatment for relapsing-remitting multiple sclerosis, is now available in 51 countries and recently gained approval for delaying conversion to clinically definite multiple sclerosis in patients with clinically isolated syndromes. Over the last 10-15 years, abundant research has better characterized the immunomodulatory activities and clinical efficacy and safety of GA… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Similar Papers

Loading similar papers…